Smagin V G, Vinogradov V A, Bulgakov S A, Propisnova E P, Titov M I
Ter Arkh. 1987;59(2):44-8.
The paper is concerned with the results of clinical assessment of a new peptide drug dalargin in therapy of duodenal peptic ulcer. Assessment of the efficacy of dalargin was compared to that of tagamet and placebo using double "blind" control. A total of 180 males with exacerbation of duodenal ulcer were examined, of them 90 received dalargin only, 70 received tagamet and 20 persons participated in an experiment based on a method of double "blind" control. An average period of duodenal ulcer healing in the patients on dalargin therapy was 21.4 +/- 1.2 days, and by the 28th day complete cicatrization was observed in 87.5% of the patients. In tagamet therapy an average period of cicatrization was 23.7 +/- 1.8 days, by the 28th day ulcer healing was observed in 87.3%. With placebo ulcer healing by the 4th week was observed in 30% of the examinees, in dalargin therapy in 80%. A conclusion was made of high efficacy of dalargin for therapy of peptic ulcer.
本文关注一种新型肽类药物达拉argin治疗十二指肠消化性溃疡的临床评估结果。使用双盲对照，将达拉argin的疗效评估与泰胃美和安慰剂的疗效评估进行了比较。总共检查了180名十二指肠溃疡加重的男性，其中90人仅接受达拉argin治疗，70人接受泰胃美治疗，20人参与了基于双盲对照方法的实验。接受达拉argin治疗的患者十二指肠溃疡愈合的平均时间为21.4±1.2天，到第28天，87.5%的患者观察到完全瘢痕化。在泰胃美治疗中，平均瘢痕化时间为23.7±1.8天，到第28天，87.3%的患者观察到溃疡愈合。使用安慰剂时，4周内30%的受检者溃疡愈合，而在达拉argin治疗中为80%。得出结论，达拉argin治疗消化性溃疡疗效显著。
